Genmab A/S (NASDAQ:GMAB - Free Report) - Stock analysts at HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for Genmab A/S in a research note issued to investors on Thursday, April 24th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of $0.21 for the quarter, up from their previous estimate of $0.18. HC Wainwright currently has a "Buy" rating and a $37.00 target price on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S's Q2 2025 earnings at $0.44 EPS, Q3 2025 earnings at $0.45 EPS and FY2026 earnings at $1.85 EPS.
GMAB has been the topic of a number of other reports. Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Truist Financial cut their price target on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Finally, Sanford C. Bernstein cut Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Genmab A/S has an average rating of "Moderate Buy" and a consensus target price of $39.17.
Read Our Latest Research Report on GMAB
Genmab A/S Price Performance
Shares of NASDAQ GMAB traded up $0.04 during mid-day trading on Friday, hitting $20.63. The company had a trading volume of 783,386 shares, compared to its average volume of 1,050,934. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $30.41. The company has a market capitalization of $13.66 billion, a PE ratio of 11.86, a price-to-earnings-growth ratio of 2.65 and a beta of 1.07. The business's 50-day simple moving average is $20.47 and its 200 day simple moving average is $21.02.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%.
Institutional Trading of Genmab A/S
A number of hedge funds and other institutional investors have recently made changes to their positions in GMAB. AIMZ Investment Advisors LLC purchased a new position in shares of Genmab A/S during the fourth quarter worth about $3,525,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Genmab A/S by 229.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company's stock worth $1,033,000 after buying an additional 34,652 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Genmab A/S by 33.4% during the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock worth $120,000 after buying an additional 1,442 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Genmab A/S during the fourth quarter worth about $2,463,000. Finally, Sei Investments Co. grew its holdings in shares of Genmab A/S by 55.2% during the fourth quarter. Sei Investments Co. now owns 57,702 shares of the company's stock worth $1,205,000 after buying an additional 20,525 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
See Also
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
